Induction of Strong and Specific Humoral and T-helper 1 Cellular Responses by HBsAg Entrapped in the Methanobrevibacter smithii Archaeosomes.

BACKGROUND: Application of adjuvants with microbial origins is a recently highlighted approach in the vaccinology trials. Archaeosomes are among these microbial compounds with both adjuvant and liposomal activities and features. METHODS: In the present study, recombinant HBsAg encapsulated into Methanobrevibacter smithii (M. smithii) archaeosomes. Balb/c mice immunized with this compound and humoral and cytokine secretion pattern of immunized models analyzed. RESULTS: Frequency of IFN-γ secreting cells in the HBsAg-containing archaeosomes group was significantly higher than HBsAg and HBsAg(+)C/IFA groups (p≤0.05). IgG2a titer in the sera of HBsAg-containing archaeosomes group was also significantly higher than this subclass titer in the other groups (p≤ 0.05). CONCLUSION: Analysis of induced responses revealed the immunopotentiating characteristics of M. smithii archaeosomes in the induction of T-helper 1 responses according to the dominance of IgG2a subtype and IFN-γ secreting splenocytes of immunized mice.

Gadolinium-deferasirox-D-glucosamine: novel anti-tumor and MR molecular (theranostic) imaging agent.

UNLABELLED: TARGET AND PURPOSE: Cancer and heart disease are hard maladies in human communities. To recognize these kinds of diseases in primary states can help for remission and decreasing the expenses. One of the best techniques for recognizing is imaging of the tissue. METHODS: The main reason of this study is to survey the design of molecules Gd3+ -Defrasirox-DG as a type of glucose labeled with gadolinium to capture more specific cancer tissue and heart by MRI instrument as a technique extremely accurate and sensitive not too costly and lack of radioactive half-life compared with radioactive 18FDG as competing compound. RESULT: In this research, glucose is combined with Deferasirox for making complexes with gadolinium. With replacing the new compound of advanced imaging technology, it transferred from nuclear medicine to Radiology and the results were evaluated in vitro and in vivo that indicated the success in imaging of the heart and cancer in animal tumor model. CONCLUSION: The mechanism of cancer cells death is through activation of TNF-α system. At present, due to the lack of radiation and radioactive half-life and low production cost and high access to MRI compared with PET, this compound can be considered as 18FDG opponent in the near future as the new MRI successor agent.

Nanosized tamoxifen-porphyrin-glucose [TPG] conjugate: novel selective anti-breast-cancer agent, synthesis and in vitro evaluations.

Tumor and especially breast cancer is among the most common causes of death worldwide. Finding novel nanosized therapeutic compounds have important role to decrease the chance of death and increase the survival. Cancer cells are highly attractive to glucose [with a nanosize bimolecular structure 1nm] as an energy source more than normal cell and nanosized therapeutics due to possessing different pharmacokinetic and pharmacodynamic have advantageous over classical dosage forms in cancer therapy. The aim of the study was to synthesize Glucosamin-Porphyrin-Tamoxifen [TPG] nanosized complex as a novel selective biocompatible anti breast cancer agent. After the synthesis procedure, this complex was purified and then tested In Vitro on breast cancer cells [MCF-7] in the absence or presence of the red light and found totally successful. The results showed a good anti breast cancer activity mediated by the activation of TNF-α and necrosis/apoptosis pathways for the nanosized complex with no alteration effects on blood PT/APTT and glucose or hexokinase levels/ activity. TPG nanoconjugate seems to be very good opponents to current anti breast cancer drugs and needs to be further investigated in near future.